中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (10): 987-992.doi: 10.3969/j.issn.1000-6621.2021.10.002
首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 《中国防痨杂志》编辑委员会
收稿日期:
2021-08-03
出版日期:
2021-10-10
发布日期:
2021-10-11
基金资助:
Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute , Editorial Board of Chinese Journal of Antituberculosis
Received:
2021-08-03
Online:
2021-10-10
Published:
2021-10-11
摘要:
结核病疫情依然严峻,迫切需要抗结核新药。新药临床试验是新药研发的最重要阶段,早期杀菌活性(early bactericidal activity,EBA)研究是新型抗结核药物首次用于结核病患者治疗时进行的临床研究,也是单个抗结核药物和新的联合方案临床评价的关键。为了规范开展以及更好地推进我国抗结核新药研发进程,首都医科大学附属北京胸科医院和《中国防痨杂志》编辑委员会共同组织结核病临床研究和基础研究领域的专家,经反复讨论,撰写了《抗结核新药早期杀菌活性研究方法专家共识》,就抗结核新药EBA的意义、设计、实施,以及影响因素等内容进行阐述。
首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 《中国防痨杂志》编辑委员会. 抗结核新药早期杀菌活性研究方法专家共识[J]. 中国防痨杂志, 2021, 43(10): 987-992. doi: 10.3969/j.issn.1000-6621.2021.10.002
Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute , Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 987-992. doi: 10.3969/j.issn.1000-6621.2021.10.002
[1] |
Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis, 1980, 121(6): 939-949. doi: 10.1164/arrd.1980.121.6.939.
doi: 10.1164/arrd.1980.121.6.939 |
[2] |
Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther, 2003, 1(1): 141-155. doi: 10.1586/14787210.1.1.141.
doi: 10.1586/14787210.1.1.141 URL |
[3] |
Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med, 2003, 167(10): 1348-1354. doi: 10.1164/rccm.200210-1125OC.
doi: 10.1164/rccm.200210-1125OC URL |
[4] |
Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb), 2008, 88 Suppl 1:S75-S83. doi: 10.1016/S1472-9792(08)70038-6.
doi: 10.1016/S1472-9792(08)70038-6 URL |
[5] |
Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomized trial. Lancet, 2012, 380(9846): 986-993. doi: 10.1016/S0140-6736(12)61080-0.
doi: 10.1016/S0140-6736(12)61080-0 URL |
[6] |
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, et al. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. Am J Respir Crit Care Med, 2020, 201(11): 1416-1424. doi: 10.1164/rccm.201910-1960OC.
doi: 10.1164/rccm.201910-1960OC URL |
[7] |
Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother, 2010, 54(8): 3402-3407. doi: 10.1128/AAC.01354-09.
doi: 10.1128/AAC.01354-09 URL |
[8] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427 URL |
[9] |
Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother, 2008, 52(8): 2831-2835. doi: 10.1128/AAC.01204-07.
doi: 10.1128/AAC.01204-07 pmid: 18505852 |
[10] |
Paramasivan CN, Herbert D, Umapathy KC, et al. Early bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide in pulmonary tuberculosis patients. Indian J Med Res, 1994, 100: 1-4.
pmid: 7927544 |
[11] |
Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother, 2000, 45(6): 859-870. doi: 10.1093/jac/45.6.859.
doi: 10.1093/jac/45.6.859 URL |
[12] |
Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis, 2006, 10(6): 605-612.
pmid: 16776446 |
[13] |
Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis, 2010, 29(12): 1561-1565. doi: 10.1007/s10096-010-1043-7.
doi: 10.1007/s10096-010-1043-7 URL |
[14] |
McAulay K, Saito K, Warrier T, et al. Differentially detectable Mycobacterium tuberculosis cells in sputum from treatment-naive subjects in Haiti and their proportionate increase after initiation of treatment. mBio, 2018, 9(6): e02192-18. doi: 10.1128/mBio.02192-18.
doi: 10.1128/mBio.02192-18 |
[15] |
Epstein MD, Schluger NW, Davidow AL, et al. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest, 1998, 113(2): 379-386. doi: 10.1378/chest.113.2.379.
doi: 10.1378/chest.113.2.379 pmid: 9498955 |
[16] |
Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis, 2010, 14(5): 560-570.
pmid: 20392348 |
[17] |
Pheiffer C, Carroll NM, Beyers N, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis, 2008, 12(7): 792-798.
pmid: 18544206 |
[18] |
Abe C, Hosojima S, Fukasawa Y, et al. Comparison of MB-Check,BACTEC, and egg-based media for recovery of mycobacteria. J Clin Microbiol, 1992, 30(4): 878-881. doi: 10.1128/jcm.30.4.878-881.1992.
doi: 10.1128/jcm.30.4.878-881.1992 pmid: 1572974 |
[19] |
Chew WK, Lasaitis RM, Schio FA, et al. Clinical evaluation of the mycobacteria growth indicator tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of mycobacterium species. J Med Microbiol, 1998, 47(9): 821-827. doi: 10.1099/00222615-47-9-821.
doi: 10.1099/00222615-47-9-821 pmid: 9736164 |
[20] |
Pfyffer GE, Welscher HM, Kissling P, et al. Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol, 1997, 35(2): 364-368. doi: 10.1128/jcm.35.2.364-368.
doi: 10.1128/jcm.35.2.364-368.1997 pmid: 9003597 |
[21] |
Somoskövi A, Magyar P. Comparison of the mycobacteria growth indicator tube with MB redox, Löwenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens. J Clin Microbiol, 1999, 37(5): 1366-1369. doi: 10.1128/JCM.37.5.1366-1369.1999.
doi: 10.1128/JCM.37.5.1366-1369.1999 pmid: 10203488 |
[22] |
Diacon AH, Dawson R, du Bois J, et al. Phase Ⅱ dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother, 2012, 56(6): 3027-3031. doi: 10.1128/AAC.06125-11.
doi: 10.1128/AAC.06125-11 URL |
[23] |
Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis, 2011, 15(7): 949-954. doi: 10.5588/ijtld.10.0616.
doi: 10.5588/ijtld.10.0616 pmid: 21682970 |
[24] |
Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother, 2013, 57(5): 2199-2203. doi: 10.1128/AAC.02243-12.
doi: 10.1128/AAC.02243-12 URL |
[25] |
Diacon AH, Maritz JS, Venter A, et al. Time toliquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect, 2012, 18(7): 711-717. doi: 10.1111/j.1469-0691.2011.03626.x.
doi: 10.1111/j.1469-0691.2011.03626.x URL |
[26] |
Fenner F. The enumeration of viable tubercle bacilli by surface plate counts. Am Rev Tuberc, 1951, 64(4): 353-380. doi: 10.1164/art.1951.64.4.353.
doi: 10.1164/art.1951.64.4.353 |
[27] |
Walsh KF, McAulay K, Lee MH, et al. Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. Antimicrob Agents Chemother, 2020, 64(5): e01956-19. doi: 10.1128/AAC.01956-19.
doi: 10.1128/AAC.01956-19 |
[28] |
Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert Rev Anti Infect Ther, 2014, 12(2): 223-237. doi: 10.1586/14787210.2014.870884.
doi: 10.1586/14787210.2014.870884 URL |
[29] |
Sirgel F, Venter A, Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J Antimicrob Chemother, 2001, 47(2): 177-182. doi: 10.1093/jac/47.2.177.
doi: 10.1093/jac/47.2.177 URL |
[30] |
Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis, 1992, 73(1): 33-38. doi: 10.1016/0962-8479(92)90077-W.
doi: 10.1016/0962-8479(92)90077-W URL |
[31] |
Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med, 1997, 156(3 Pt 1): 895-900. doi: 10.1164/ajrccm.156.3.9609132.
doi: 10.1164/ajrccm.156.3.9609132 URL |
[32] |
Hafner R, Cohn JA, Wright DJ, et al. Early bactericidalactivity of isoniazid in pulmonary tuberculosis. Optimization of methodology.The DATRI008 Study Group. Am J Respir Crit Care Med, 1997, 156(3 Pt 1): 918-923. doi: 10.1164/ajrccm.156.3.9612016.
doi: 10.1164/ajrccm.156.3.9612016 URL |
[33] |
Tessema B, Beer J, Emmrich F, et al. Rate ofrecovery of Mycobacterium tuberculosis from frozen acid-fast-bacillussmear-positive sputum samples subjected to long-term storage in Northwest Ethiopia. J Clin Microbiol, 2011, 49(7): 2557-2561. doi: 10.1128/JCM.00059-11.
doi: 10.1128/JCM.00059-11 pmid: 21562105 |
[34] |
Chambers HF, Kocagöz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis, 1998, 26(4): 874-877. doi: 10.1086/513945.
doi: 10.1086/513945 pmid: 9564467 |
[35] |
Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med, 2001, 1: 2. doi: 10.1186/1471-2466-1-2.
doi: 10.1186/1471-2466-1-2 pmid: 11737875 |
[36] |
Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infect Dis J, 2008, 2: 59-76. doi: 10.2174/1874279300802010059.
doi: 10.2174/1874279300802010059 pmid: 23814629 |
[37] |
Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle, 1985, 66(3): 219-225. doi: 10.1016/0041-3879(85)90040-6.
doi: 10.1016/0041-3879(85)90040-6 pmid: 3931319 |
[38] |
Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of rifabutin inpatients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother, 1993, 32(6): 867-875. doi: 10.1093/jac/32.6.867.
doi: 10.1093/jac/32.6.867 URL |
[39] |
Kolwijck E, Mitchell M, Venter A, et al. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies. J Clin Microbiol, 2013, 51(4): 1094-1098. doi: 10.1128/JCM.02751-12.
doi: 10.1128/JCM.02751-12 pmid: 23345289 |
[40] |
Svensson RJ, Svensson EM, Aarnoutse RE, et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. J Infect Dis, 2018, 218(6): 991-999. doi: 10.1093/infdis/jiy242.
doi: 10.1093/infdis/jiy242 pmid: 29718390 |
[41] | Botha FJ, Sirgel FA, Parkin DP, et al. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J, 1996, 86(2): 155-158. |
[42] |
Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis, 1993, 148(6 Pt 1): 1547-1551. doi: 10.1164/ajrccm/148.6_Pt_1.1547.
doi: 10.1164/ajrccm/148.6_Pt_1.1547 URL |
[1] | 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版)[J]. 中国防痨杂志, 2021, 43(9): 859-866. |
[2] | 首都医科大学附属北京胸科医院, 《中国防痨杂志》编辑委员会. 抗结核药治疗药物监测临床应用专家共识[J]. 中国防痨杂志, 2021, 43(9): 867-873. |
[3] | 中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志, 2021, 43(9): 874-878. |
[4] | 周文强, 张爽, 初乃惠. 耐药肺结核全口服治疗方案研究的现状和展望[J]. 中国防痨杂志, 2021, 43(9): 879-882. |
[5] | 逄宇, 高兴辉, 汤一苇, 高孟秋. 基于结核病宿主免疫反应的实验室检测技术及其临床应用[J]. 中国防痨杂志, 2021, 43(9): 883-892. |
[6] | 丁彩红, 熊瑜, 王庆, 高绪胜, 郝焱. 含贝达喹啉方案治疗耐多药肺结核的早期疗效和安全性研究[J]. 中国防痨杂志, 2021, 43(9): 893-898. |
[7] | 吴国兰, 高静韬, 陈晓红, 陈力舟, 翁丽珍, 郭志平, 陈秀平, 林剑东, 陈素霞, 高孟秋, 刘宇红. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的近期疗效及安全性分析[J]. 中国防痨杂志, 2021, 43(9): 899-904. |
[8] | 石文卉, 初乃惠. 耐药肺结核患者氟喹诺酮类药物耐药情况及影响因素[J]. 中国防痨杂志, 2021, 43(9): 905-909. |
[9] | 张婷, 苏倩, 吴成果, 汪清雅, 雷蓉蓉, 陈健. 重庆市肺结核患者直接医疗费用及其影响因素分析[J]. 中国防痨杂志, 2021, 43(9): 910-915. |
[10] | 赵秀娟, 莫菁莲, 孙涛, 刘琳, 钟业腾, 裴华, 夏乾峰. 2015—2019年海南省省级结核病定点医疗机构收治的肺结核患者耐药特征及相关因素分析[J]. 中国防痨杂志, 2021, 43(9): 916-923. |
[11] | 林建, 林淑芳, 戴志松, 赵永, 周银发, 张添林, 魏淑贞. 2016—2019年福建省结核病耐药监测结果分析[J]. 中国防痨杂志, 2021, 43(9): 924-928. |
[12] | 李婷, 何金戈, 夏岚, 陈闯, 肖月, 逯嘉, 王丹霞. 新型冠状病毒肺炎疫情对四川省结核病患者登记情况的影响分析[J]. 中国防痨杂志, 2021, 43(9): 929-938. |
[13] | 易一行, 喻容, 石国民, 马小华, 肖四方, 税剑, 范任华, 向延根. 基于16S rRNA V4区高通量测序的初治菌阳肺结核患者肠道菌群构成与表型分析[J]. 中国防痨杂志, 2021, 43(9): 939-946. |
[14] | 周莹宇, 付雷, 张炜焱, 王彬, 陈曦, 陆宇, 陈效友. 不同耐药类型结核分枝杆菌毒力变化的初步研究[J]. 中国防痨杂志, 2021, 43(9): 952-960. |
[15] | 马婷婷, 任斐, 马进宝, 杨翰. 异烟肼耐药肺结核患者对丙硫异烟胺和对氨基水杨酸的耐药情况分析[J]. 中国防痨杂志, 2021, 43(9): 961-964. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||